BioTelemetry Inc (NASDAQ:BEAT) has been assigned a consensus rating of “Hold” from the ten ratings firms that are covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $43.67.
A number of brokerages have recently issued reports on BEAT. BidaskClub raised BioTelemetry from a “hold” rating to a “buy” rating in a research report on Friday, March 9th. Zacks Investment Research downgraded BioTelemetry from a “hold” rating to a “sell” rating in a research report on Thursday, February 8th. TheStreet downgraded BioTelemetry from a “b-” rating to a “c” rating in a research report on Tuesday, March 20th. Finally, Dougherty & Co reaffirmed a “buy” rating and set a $41.00 price target (up from $40.00) on shares of BioTelemetry in a research report on Friday, February 23rd.
In related news, insider Fred Broadway sold 54,158 shares of the company’s stock in a transaction on Tuesday, March 13th. The stock was sold at an average price of $34.17, for a total value of $1,850,578.86. Following the transaction, the insider now directly owns 64,880 shares of the company’s stock, valued at approximately $2,216,949.60. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 8.30% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. increased its position in shares of BioTelemetry by 7.4% in the 4th quarter. BlackRock Inc. now owns 4,093,837 shares of the medical research company’s stock valued at $122,405,000 after acquiring an additional 281,415 shares during the period. Bank of New York Mellon Corp increased its position in shares of BioTelemetry by 39.2% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,435,701 shares of the medical research company’s stock valued at $47,379,000 after acquiring an additional 404,107 shares during the period. Hood River Capital Management LLC increased its position in shares of BioTelemetry by 31.1% in the 4th quarter. Hood River Capital Management LLC now owns 1,190,626 shares of the medical research company’s stock valued at $35,600,000 after acquiring an additional 282,687 shares during the period. Macquarie Group Ltd. increased its position in shares of BioTelemetry by 8,866.8% in the 4th quarter. Macquarie Group Ltd. now owns 756,263 shares of the medical research company’s stock valued at $22,612,000 after acquiring an additional 747,829 shares during the period. Finally, Pembroke Management LTD increased its position in shares of BioTelemetry by 19.1% in the 4th quarter. Pembroke Management LTD now owns 534,900 shares of the medical research company’s stock valued at $15,993,000 after acquiring an additional 85,600 shares during the period. 87.13% of the stock is currently owned by hedge funds and other institutional investors.
Shares of BEAT stock traded up $0.70 during trading hours on Wednesday, reaching $31.30. 42,841 shares of the company’s stock were exchanged, compared to its average volume of 407,402. The company has a market cap of $1,001.42, a PE ratio of 31.55, a PEG ratio of 1.54 and a beta of 0.86. The company has a current ratio of 1.77, a quick ratio of 1.66 and a debt-to-equity ratio of 0.80. BioTelemetry has a fifty-two week low of $23.30 and a fifty-two week high of $39.20.
BioTelemetry (NASDAQ:BEAT) last issued its quarterly earnings results on Thursday, February 22nd. The medical research company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.24 by $0.08. The business had revenue of $91.70 million for the quarter, compared to the consensus estimate of $88.33 million. BioTelemetry had a positive return on equity of 14.54% and a negative net margin of 5.56%. The business’s quarterly revenue was up 69.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.23 earnings per share. equities analysts forecast that BioTelemetry will post 1.25 earnings per share for the current year.
WARNING: This story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another publication, it was copied illegally and reposted in violation of international copyright laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/09/biotelemetry-inc-beat-receives-43-67-average-target-price-from-analysts.html.
BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.